A firm based invests strategically on behalf of a global pharmaceutical company. The firm will invest mostly in therapeutics, and a bit in digital health.

The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $15M over the life of an investment for therapeutics companies, and slightly less for digital health companies. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments – the firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities beyond the parent company’s core areas of business.  The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology (esp. new therapeutic modalities, such as cell / gene therapy), regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology and immunomodulation), tissue regeneration (stem cells, NCEs, biologics), anti-infectives with novel MOA, and microbiome; within digital health, the firm is interested in patient care management (i.e. diagnosis and monitoring of disease, prevention of onset and progression of disease including digital biomarkers, population management), medication adherence, digital companion therapy, and digital therapy as stand alone. The firm will also consider opportunities in other indication areas outside of the aforementioned key areas of interest. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance the parent company. The firm only invests in privately held companies.  The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Western Europe current invests from their third fund which focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2.  (i.e Series A and Series B)

Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, and is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment office is actively involved in the management of a diverse portfolio of investments in private equity and venture capital.

The firm accelerates commercialization of ground-breaking innovation through investments, experienced hands-on management and the intelligent use of partnering. The firm focuses on a number of areas around which it has build teams of senior execs, world leading experts and advisors drawn from industry, finance, academia and regulatory bodies to support and accelerate its ventures.

In Life Sciences, the firm typically invests at seed stage or before a company has been formed and develop these early opportunities through preclinical phase; at late preclinical/early clinical stage the firm gets co-investors involved. The firm prefers areas where there are multiple capital efficient routes to market, with opportunities for early proof of concept or early out-licensing or exits.

Currently, the firm manages a $150M fund and makes investments from $100K to $10M, depending on the opportunity. The firm is seeking a couple of opportunities to add to its portfolio. The firm invests in companies based in the USA and/or Europe.

The firm is sector- and stage- agnostic. In terms of biotech indications, the firm has invested in anti-infectives and particularly antimicrobial resistance, as well as immuno-modulatory anti-inflammatory indications and orphan and rare diseases.

The firm looks for a strong management team with proven track-record and a ground-breaking technology addressing an unmet need. The firm seeks to take significant stakes and board seats. In addition, the firm may provide active support leveraging its network of senior execs, experts and advisors to accelerate the development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group with multiple investment vehicles manages approx. $1.5B targeted on healthcare and life science under management. The firm launched a new vehicle in 2020 to invest in digital health technologies. The group will invest $1-2M, mainly in seed-series A companies developing software-based digital technologies. While the firm will invest globally, they are looking for companies targeting the US market.

The firm is interested in software-based digital health companies. The group will not invest in wearables or smart devices. The firm invests primarily in B2B or B2B2C companies, and looks for technologies that have clear cost saving or revenue generating aspect for clients.

The firm is a very active investor, leveraging their network and broad-cross sector activity to help their portfolio companies. The group is looking for companies that, at minimum, have a viable understanding of the US healthcare market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital and growth equity firm providing expertise and funding to companies with global ambitions in healthcare technologies. The firm is headquartered in Western Europe with teams in the US. The firm is currently making investments from a relatively new fund closed in 2021. The firm prefers to be the lead investor and possibly co-lead, seeking to allocate US$20-30 million (in equity) per company through subsequent rounds of investment. The firm invests in growth-stage companies that are based in the US and Europe and is actively seeking new investment opportunities.

The firm invests in medical devices, digital health, and diagnostic technologies. The firm focuses on companies that can address a specific unmet medical need or deliver considerable improvements to care delivery. Innovative healthcare technologies with a therapeutic focus are of high interest. The firm is opportunistic in terms of subsectors and indications and seeks companies that are in commercial ramp-up.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. Companies seeking investment should be led by a strong and experienced management team and have the support of technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in Western Europe, with additional offices in USA and Asia, has a fund dedicated to investing in 25-28 companies in Seed to Series A financing rounds. The firm seeks to invest in innovations directly related to the prevention of age-associated diseases, extension of a healthy lifespan, and improving the performance of humans and animals. The firm’s initial check size can range from $500K – 1.5M, and the firm is open to global opportunities.

Within life sciences, the firm is most interested in therapeutics and diagnostics companies, and will also consider digital health. Medical devices with traditional regulatory pathways are generally out of scope for the firm. Within these sectors, interest areas can include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and more. That said, the firm has no strong interest in particular technologies and is open to all modalities. The firm is also opportunistic in terms of stage of development.

The firm seeks companies with strong, protectable IP with clear origins and ownership, backed by a diverse team with a strong track record and technologies with validated proof of concept. The firm has a 3-step due diligence process which includes: (1) initial review, (2) additional review – where the firm looks more closely into main differentiating factors of the company (IP, business model, etc.), and (3) final review. The firm is open to leading, co-leading, or co-investing, and has a strong co-investment and syndication network of likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.